Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppression
This study identifies specific proteins in neuroblastoma that may contribute to T cell suppression, but the clinical relevance and direct effects on T cell activation remain unvalidated.
Where it sits
this study against the rest of the pe 22-28 corpusSummary and findings
This study mapped secreted factors from 16 genetically diverse patient-derived neuroblastoma tumoroids using LC-MS to identify immunosuppressive factors. The secretomes were found to suppress T cell activation, proliferation, and cytotoxicity. Neuropeptide Y (NPY) was identified as a biomarker for extracellular vesicle (EV) secretion, with no validated direct effects on T cell activation.
Abstract
Immunosuppressive tumor microenvironments in solid tumors hamper the efficacy of immunotherapies, including CAR T-cell therapy. To identify immunosuppressive secreted factors in high-risk neuroblastoma, a childhood solid tumor with a 5-year overall survival of below 60%, we mapped secreted factors of 16 genetically diverse patient-derived neuroblastoma tumoroids by LC-MS. The secretomes suppressed T cell activation, proliferation and cytotoxicity to varying extents, suggesting that this panel constituted a valuable discovery foundation to identify clinically relevant immunosuppressive factors. 29 proteins were significantly enriched in highly suppressive secretomes, of which Neuropeptide Y (NPY) had the highest correlation with functionally-determined immunosuppression. No direct or indirect effect of NPY on (CAR) T cell activation could be validated. Instead, NPY proved to be a biomarker for extracellular vesicle (EV) secretion. Finally, we demonstrated that neuroblastoma-derived EVs potently suppress T cell activation. Altogether, this study provides an atlas of the neuroblastoma secretome and reveals immunosuppressive effects of EVs on T cells. These insights contribute to the understanding of the immunosuppressive neuroblastoma TME.
Background
This paper addresses the role of neuroblastoma in immune evasion, specifically focusing on how the secretome of neuroblastoma cells may influence T cell activity. Prior research has indicated that tumor-derived factors can modulate immune responses, but the specific contributions of extracellular vesicles (EVs) in this context were not well understood. This study aims to clarify the mechanisms by which neuroblastoma may suppress T cell function through its secreted factors.
Methods
The study employs proteomic profiling to analyze the secretome of neuroblastoma cells, focusing on the characterization of extracellular vesicles. The specific population studied, sample size (n), duration, and primary versus secondary outcome measures are not detailed in the abstract. The methodology appears to center on identifying components within the secretome that may have immunosuppressive effects.
Results
Not reported in abstract.
Interpretation
The findings suggest a potential mechanism by which neuroblastoma can evade immune surveillance through the secretion of EVs that suppress T cell activity. However, without specific numeric findings or effect sizes reported, it is difficult to assess the clinical significance of these results. The lack of detailed methodology and findings limits the ability to draw robust conclusions about the implications for treatment or further research.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.